Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy-Reference-Cited by-同舟云学术

Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy

Published:2019-09-30 Issue:4 Volume:235 Page:3142-3156
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J Cell Physiol

Author:

Derakhshani Afshin¹^ORCID,Rezaei Zohreh²,Safarpour Hossein³,Sabri Morteza²,Mir Atefeh²,Sanati Mohammad Amin³,Vahidian Fatemeh¹,Gholamiyan Moghadam Ali⁴,Aghadoukht Ali⁵,Hajiasgharzadeh Khalil¹,Baradaran Behzad¹^ORCID

Affiliation:

1. Immunology Research Center Tabriz University of Medical Sciences Tabriz Iran

2. Department of Biology, Faculty of Sciences University of Sistan and Balouchestan Zahedan Iran

3. Cellular & Molecular Research Center Birjand University of Medical Sciences Birjand Iran

4. Department of Biological Science, Faculty of Science University of Damghan Damghan Iran

5. Department of Biological Science, Faculty of Science University of Kurdistan Sanandaj Iran

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcp.29216

Reference130 articles.

1. Src activation by β-adrenoreceptors is a key switch for tumour metastasis

2. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

3. Treatment of HER2-positive breast cancer: current status and future perspectives

4. Baselga J. Albanell J. Molina M. A. &Arribas J.(2001).Mechanism of action of trastuzumab and scientific update. Paper presented at the seminars in oncology.

5. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy;European Journal of Medicinal Chemistry;2024-10

2. Deep learning-assisted monitoring of trastuzumab efficacy in HER2-Overexpressing breast cancer via SERS immunoassays of tumor-derived urinary exosomal biomarkers;Biosensors and Bioelectronics;2024-08

3. Bioinformatics and In Vitro Study Reveal ERα as The Potential Target Gene of Honokiol to Enhance Trastuzumab Sensitivity in HER2+ Trastuzumab-Resistant Breast Cancer Cells;Computational Biology and Chemistry;2024-08

4. Relative efficacy of antibody-drug conjugates and other anti-HER2 treatments on survival in HER2-positive advanced breast cancer: a systematic review and meta-analysis;BMC Cancer;2024-06-08

5. A bibliometric and visualization analysis of research trends and hotspots on targeted therapy for breast cancer from 2003 to 2022;Frontiers in Oncology;2024-06-04